Related Experiment Video
Updated: Jan 27, 2026
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Abstract:
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Insights
Idiosyncratic drug-induced liver injury (DILI) presents diagnostic challenges due to varied presentations and lack of biomarkers. These guidelines offer evidence-based strategies for managing this severe liver disorder.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Toxicology
Background:
- Idiosyncratic drug-induced liver injury (DILI) is a complex hepatologic challenge.
- Diagnosis is difficult due to diverse clinical phenotypes and lack of specific biomarkers.
- Potential hepatotoxins include pharmaceuticals, herbs, and dietary supplements.
Framework:
- Guidelines focus on risk factors, diagnostic approaches, and management strategies for DILI.
- Emphasizes the need for high clinical awareness and exclusion of other liver disease causes.
- Addresses the severe complication of acute liver failure secondary to DILI.
Implementation:
- Summarizes current evidence for clinical practice.
- Aims to improve diagnostic certainty and patient outcomes.
- Provides strategies for risk minimization.
Implications:
- Aims to reduce the burden of DILI on patients and healthcare systems.
- Highlights the need for further research into biomarkers and therapies.
- Supports evidence-based decision-making for hepatologists and clinicians treating DILI.
Related Concept Videos
01:29Acute Kidney Injury III: Clinical Manifestations
01:26Guidelines for Nursing Documentation II
Timely documentation is crucial to ensure continuity of care for patients. Any delays in recording or reporting medical information can result in medical errors and even adverse patient outcomes. From medication administration to diagnostic test results, every detail must be accurately and promptly documented to provide the best possible care for patients.
01:06Legal Guidelines for Documentation
01:23Guidelines for Sketching a Curve
01:11Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
01:30Guidelines for Nursing Documentation I
Factual:
The following points emphasize the significance of upholding accurate and unbiased documentation in healthcare.